We are live on ! Find out more

Tempus AI

TEM

Market cap $12.3B

67.99 USD

-2.94

4.14%

At close Updated Oct 12, 4:00 PM EDT

Pre-market

After hours

67.84

-0.15

0.22%

1 day

-4.14%

5 days

-19.98%

1 month

9.29%

3 months

21.56%

6 months

47.87%

Year to date

9.03%

1 year

-28.03%

5 years

68.92%

10 years

68.92%

About: Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.

Employees: 3,800

Healthcare Health Information Services

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 45.6%

Neutral 44.3%

Negative 10.1%

Zacks Investment Research

Tempus AI Expands Strategic Collaborations to Drive Future Growth

TEM is expanding its precision medicine footprint through strategic collaborations with Moderna, Merck and Recursion, paving the way for future revenue growth.

Tempus AI Expands Strategic Collaborations to Drive Future Growth

Zacks Investment Research

Should You Buy, Hold or Sell Tempus AI Stock Amid AI Boom?

TEM's strong data licensing growth, AI-driven innovations and rising shares favor holding the stock, but premium valuation and reimbursement risks warrant caution.

Should You Buy, Hold or Sell Tempus AI Stock Amid AI Boom?

Tempus AI Doubles Down On Moderna and Merck Cancer Vaccine Infrastructure

Tempus Inc. (NASDAQ:TEM) on Wednesday expanded its multi-year collaboration for intismeran autogene (V940/mRNA-4157) individualized neoantigen therapy (INT) combined with Keytruda (pembrolizumab) for completely resected stage IIB-IV melanoma and other cancer types.

Tempus AI Doubles Down On Moderna and Merck Cancer Vaccine Infrastructure

Tempus Announces Multi-Year Collaboration with Moderna and Merck

CHICAGO--(BUSINESS WIRE)--Tempus (NASDAQ: TEM) today announced an expanded, multi-year collaboration to support the potential commercialization of intismeran autogene (V940/mRNA-4157), a novel, potential first-in-class individualized neoantigen therapy (INT) being evaluated in combination with KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy, in patients with completely resected stage IIB-IV melanoma and other cancer types. Intismeran autogene is jointly developed by Moderna and Merck, know.

Tempus Announces Multi-Year Collaboration with Moderna and Merck

Zacks Investment Research

Here's How Tempus AI is Capitalizing on AI-ECG Market Growth

TEM is expanding its cardiovascular portfolio with FDA-cleared AI-ECG tools targeting complex cardiac conditions.

Here's How Tempus AI is Capitalizing on AI-ECG Market Growth

Schaeffers Research

10 Stocks With Massive Short Squeeze Potential

Bond yields, oil prices, and inflation rhetoric have teamed up to make it tough for investors heading into Q4. Where are short sellers putting their money?

10 Stocks With Massive Short Squeeze Potential

Tempus Announces 13 Abstracts Accepted for Presentation at the European Society for Medical Oncology Congress 2026

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM) today announced that 13 abstracts have been accepted for presentation at the European Society for Medical Oncology (ESMO) Congress 2026, taking place October 23–27 in Madrid. At this year's congress, Tempus will showcase clinical research revealing insights in cancer biology, treatment response and patient outcomes across solid tumors, including prostate, breast, non-small cell lung cancer (NSCLC), renal cell carcinoma and gynecologic mali.

Tempus Announces 13 Abstracts Accepted for Presentation at the European Society for Medical Oncology Congress 2026

The Top HealthTech Questions Landing on Our Desks

Strong performance across the healthtech sector over the past two quarters has sparked renewed market interest in medical innovation. Given the volume of inquiries landing on our desks, we compiled this guide to answer a mix of the most frequent and most interesting questions we have received regarding our Healthcare Technology and Innovation Index (HTEC).

The Top HealthTech Questions Landing on Our Desks

Tempus Receives FDA Clearance for its ECG-MR AI Product Designed to Identify Undiagnosed Mitral Regurgitation

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM) today announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for Tempus ECG-MR, an AI product that analyzes standard 12-lead resting electrocardiograms (ECGs) to detect signs associated with undiagnosed moderate or severe mitral regurgitation (MR). MR is a common form of heart valve disease where blood leaks backward through the mitral valve. Because early stages are often asymptomatic or manifest as no.

Tempus Receives FDA Clearance for its ECG-MR AI Product Designed to Identify Undiagnosed Mitral Regurgitation

Top Performing Leveraged/Inverse ETFs: 09/20/2026

Top Performing Leveraged/Inverse ETFs Last Week These were last week's top performing leveraged and inverse ETFs. Note that because of leverage, these kinds of funds can move quickly.

Top Performing Leveraged/Inverse ETFs: 09/20/2026

See News Rankings

Price charts implemented using Lightweight Charts™